This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-EGFR IgG to IL2. It was expressed in CHO and purified with affinity chromatography. Ch225-IL2 fusion protein bound to human EGFR with the high affinity of the parental antibody, and was as active as the equivalent amount of rhIL2. The effect of ch225-IL2 on activated T cells was most likely mediated through IL2R. This immunocytokine was designed for treating any type of solid or non-solid cancer or malignant lymphoma.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.